These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32580593)

  • 41. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
    Avdicova M; Crasta PD; Hardt K; Kovac M
    Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Romero A; Lopez G; Dal-Ré R
    Pediatrics; 2005 Dec; 116(6):1292-8. PubMed ID: 16322149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study.
    Kim KH; Kim CS; Kim HM; Kim JD; Ma SH; Kim DH; Hwang PH; Han JW; Lee TJ; Kim JH; Karkada N; Mesaros N; Sohn WY; Kim JH
    Hum Vaccin Immunother; 2019; 15(2):317-326. PubMed ID: 30431387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of a Haemophilus influenzae type b-tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey.
    Yüksel N; Beyazova U; Balci IF; Aksakal FN; Camurdan AD; Sahin F; Rota S
    Int J Infect Dis; 2012 May; 16(5):e354-7. PubMed ID: 22387144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth.
    Gylca R; Gylca V; Benes O; Melnic A; Chicu V; Weisbecker C; Willems P; Kaufhold A
    Vaccine; 2000 Nov; 19(7-8):825-33. PubMed ID: 11115705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study.
    Berner R; Boisnard F; Thomas S; Mwawasi G; Reynolds D
    Vaccine; 2012 Jul; 30(35):5270-7. PubMed ID: 22691430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants.
    Lee J; Robinson JL; Spady DW
    BMC Pediatr; 2006 Jun; 6():20. PubMed ID: 16784533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
    Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recommended childhood immunization schedule--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(2):35-40. PubMed ID: 9011782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age.
    Tejedor JC; Omeñaca F; García-Sicilia J; Esporrín C; Molina V; Marés J; Muro M; Sanjuan P; Méndez M; Teixidor R; Enrubia M; García-Corbeira P; Boceta R; Jacquet JM; Schuerman L;
    Pediatr Infect Dis J; 2006 Oct; 25(10):943-5. PubMed ID: 17006294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.